CD8A and neoplasm: Despite finding a detectable IgG immune response in only 2 of the 6 treated patients (Figure 4A), the combined treatment seems to increase T cell reactivity to MUC1 (2–3% of T cell proliferation within the CD4 or CD8 gates to the relevant peptide) in most of the evaluable patients after 4 treatment courses (Figure 4B), and a significant correlation was found between the activation of tumor infiltrating lymphocytes and MUC1 expression in the tumor (Figure 5).